Paying user area
Try for free
Shockwave Medical Inc. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Income Statement
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Net Profit Margin since 2019
- Total Asset Turnover since 2019
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Shockwave Medical Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
ROA | = | 100 | × | Net income (loss)1 | ÷ | Total assets1 | |
---|---|---|---|---|---|---|---|
Dec 31, 2023 | = | 100 | × | ÷ | |||
Dec 31, 2022 | = | 100 | × | ÷ | |||
Dec 31, 2021 | = | 100 | × | ÷ | |||
Dec 31, 2020 | = | 100 | × | ÷ | |||
Dec 31, 2019 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 US$ in thousands
- Net Income (Loss)
- The net income experienced a significant fluctuation over the analyzed period. Initially, the company reported substantial losses, with the loss increasing from approximately -51.1 million USD in 2019 to about -65.7 million USD in 2020. In 2021, the loss sharply decreased to around -9.1 million USD, indicating an improvement. A notable turnaround occurred in 2022, achieving a positive net income of approximately 216.0 million USD. However, in 2023, the net income declined to roughly 147.3 million USD, which, while lower than 2022, remains substantially positive compared to previous years.
- Total Assets
- The total assets increased continuously during the period of 2019 to 2023. Starting at around 231.9 million USD in 2019, assets grew steadily each year, reaching approximately 272.0 million USD in 2020, 345.7 million USD in 2021, and then more than doubling in 2022 to roughly 646.1 million USD. This growth trend accelerated dramatically by 2023, with total assets surpassing 1.56 billion USD, indicating significant asset accumulation or investment growth.
- Return on Assets (ROA)
- ROA followed a trajectory correlated with net income but shows distinct volatility. It was deeply negative in 2019 and 2020, at -22.04% and -24.15% respectively, reflecting substantial losses relative to assets. In 2021, ROA improved significantly to -2.64%, signaling a move toward profitability. A sharp positive reversal occurred in 2022 with ROA reaching 33.43%, aligning with the recorded net income profit. In 2023, ROA decreased to 9.4%, indicating a reduction in asset profitability but still maintaining a positive return position.
Comparison to Competitors
Shockwave Medical Inc. | Abbott Laboratories | Elevance Health Inc. | Intuitive Surgical Inc. | Medtronic PLC | UnitedHealth Group Inc. | |
---|---|---|---|---|---|---|
Dec 31, 2023 | ||||||
Dec 31, 2022 | ||||||
Dec 31, 2021 | ||||||
Dec 31, 2020 | ||||||
Dec 31, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Comparison to Sector (Health Care Equipment & Services)
Shockwave Medical Inc., ROA, long-term trends, comparison to sector (health care equipment & services)
Shockwave Medical Inc. | Health Care Equipment & Services | |
---|---|---|
Dec 31, 2023 | ||
Dec 31, 2022 | ||
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Comparison to Industry (Health Care)
Shockwave Medical Inc. | Health Care | |
---|---|---|
Dec 31, 2023 | ||
Dec 31, 2022 | ||
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).